Khiron Life Sciences (TSXV: KHRN) has officially entered the United Kingdom’s medical cannabis market, announcing this morning the receipt of its first prescriptions for patients within the country. The prescriptions are via Project Twenty21, Europe’s first and largest medical cannabis registry study.
Project Twenty21 is working towards becoming the largest body of evidence for the effectiveness and tolerability of medical cannabis, with a target of enrolling 20,000 patients by the end of 2021. The ultimate goal of which, is to demonstrate to policymakers that medical cannabis should be as widely available and affordable as other medicines. Khiron is the exclusive Latin American supplier for the project, with Khiron branded products now available to participating UK doctors.
The first import of EU GMP medical cannabis products has now been completed, and the first prescriptions under the supply agreement now received. The company has also secured a strategic partnership with a fully certified fulfillment partner whom can provide home delivery to patients for Khiron’s medical cannabis products.
The medical cannabis market within the United Kingdom is expected to be worth nearly one billion Euro’s by 2024, with an estimated 340,000 active patients as per a study conducted by Prohibition Partners. The market has been showing significant developments for patients, with medical cannabis clinics and doctors recently receiving approval to conduct teleconsultations with patients, further opening patient access to medical cannabis.
Khiron Life Sciences last traded at $0.82 on the TSX Venture.
FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
